Peter M. Voorhees

13.9k total citations · 2 hit papers
172 papers, 5.3k citations indexed

About

Peter M. Voorhees is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Peter M. Voorhees has authored 172 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Hematology, 80 papers in Oncology and 79 papers in Molecular Biology. Recurrent topics in Peter M. Voorhees's work include Multiple Myeloma Research and Treatments (145 papers), Protein Degradation and Inhibitors (59 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Peter M. Voorhees is often cited by papers focused on Multiple Myeloma Research and Treatments (145 papers), Protein Degradation and Inhibitors (59 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Peter M. Voorhees collaborates with scholars based in United States, Canada and Germany. Peter M. Voorhees's co-authors include Robert Z. Orlowski, Deborah J. Kuhn, Paul G. Richardson, Saad Z. Usmani, Qing Chen, Elizabeth Claire Dees, Bert H. O’Neil, Sagar Lonial, John S. Strader and Asher Chanan‐Khan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter M. Voorhees

163 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

2007 591 citations Deborah J. Kuhn, Qing Chen et al. Blood profile →
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

2016 303 citations Saad Z. Usmani, Sagar Lonial et al. Blood profile →

Peers

Countries citing papers authored by Peter M. Voorhees

Since Specialization

Citations

This map shows the geographic impact of Peter M. Voorhees's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Voorhees with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Voorhees more than expected).

Fields of papers citing papers by Peter M. Voorhees

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Voorhees. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Voorhees. The network helps show where Peter M. Voorhees may publish in the future.

Co-authorship network of co-authors of Peter M. Voorhees

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M. Voorhees. A scholar is included among the top collaborators of Peter M. Voorhees based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M. Voorhees. Peter M. Voorhees is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Cindy Varga, Myra Robinson, Vikas A. Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, (unknown), Christopher J. Ferreri, (unknown), Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph	0
2	Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US 2024 ·Blood ·Binod Dhakal, Nina Kim, William S. John, Bingcao Wu, Sarah Lucht, Dee Lin, (unknown), (unknown), Bryce Van Doren, Laura Hester, (unknown), (unknown), (unknown), (unknown), Andrew J. Klink, (unknown), Bruce A. Feinberg, (unknown), (unknown), Peter M. Voorhees	1
3	Hereditary chronic neutrophilic leukemia in a four‐generation family without transformation to acute leukemia 2024 ·American Journal of Hematology ·(unknown), (unknown), (unknown), (unknown), (unknown), Nury Steuerwald, Hsih‐Te Yang, Jenny Chen, Peter M. Voorhees, Belinda R. Avalos, Lawrence J. Druhan	2
4	Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study 2024 ·British Journal of Haematology ·Ajay K. Nooka, Jonathan L. Kaufman, César A. Rodríguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson	0
5	Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study) 2024 ·Life ·Hamid Ehsan, Myra Robinson, Peter M. Voorhees, (unknown), (unknown), Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda‐Roman, (unknown), (unknown)	2
6	Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS 2024 ·Blood ·Ola Landgren, Ajai Chari, Yaël C. Cohen, Andrew Spencer, Peter M. Voorhees, Irwindeep Sandhu, Matthew Jenner, Dean Smith, Michèle Cavo, Niels W.C.J. van de Donk, Meral Beksaç, Philippe Moreau, Hartmut Goldschmidt, Diego Vieyra, Linlin Sha, L. Li, (unknown), (unknown), Robin Carson, Craig C. Hofmeister	1
7	Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). 2024 ·Journal of Clinical Oncology ·(unknown), Peter M. Voorhees, Anita D’Souza, Alfred Chung, Sascha A. Tuchman, Hana Safah, (unknown), Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, (unknown), (unknown), (unknown), (unknown), Aarif Ahsan, Xin Li, Ziyi Jin, Chetasi Talati, Shaji Kumar	8
8	BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement. 2024 ·Journal of Clinical Oncology ·Mahmoud Gaballa, Omar Castañeda Puglianini, Adam D. Cohen, Dan T. Vogl, Alfred Chung, Christopher J. Ferreri, Peter M. Voorhees, Doris K. Hansen, Krina K. Patel	1
9	A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Manisha Bhutani, David Foureau, Myra Robinson, Fei Guo, (unknown), Shebli Atrash, Barry Paul, Cindy Varga, (unknown), Mauricio Pineda‐Roman, (unknown), James T. Symanowski, (unknown), (unknown), Lawrence J. Druhan, Peter M. Voorhees, Saad Z. Usmani	2
10	A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma 2022 ·Journal of Clinical Oncology ·Anita D’Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Katja Weisel, Orlando F. Bueno, (unknown), Kevin J. Freise, (unknown), Jeremy A. Ross, Akshanth R. Polepally, (unknown), Shane Lee, Ziyi Jin, Ben Buelow, Ravi Vij, Shaji Kumar	84
11	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202) 2021 ·American Journal of Hematology ·Peter M. Voorhees, Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera, Flora Mulkey, (unknown), (unknown), (unknown), Philip L. McCarthy, Paul G. Richardson	17
12	Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug–Based Regimens 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Jai N. Patel, Myra Robinson, Megan H. Jagosky, (unknown), Justin Arnall, (unknown), (unknown), Shebli Atrash, Barry Paul, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani	5
13	Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Donald C. Moore, Justin Arnall, (unknown), (unknown), (unknown), (unknown), Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani	10
14	Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Issam S. Hamadeh, (unknown), Justin Arnall, (unknown), (unknown), (unknown), (unknown), (unknown), Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani	15
15	A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia 2019 ·Journal of Oncology Pharmacy Practice ·(unknown), Justin Arnall, Peter M. Voorhees	11
16	Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma 2019 ·Leukemia Research ·Parameswaran Hari, Claudia E. Paba‐Prada, Peter M. Voorhees, John Frye, Yulin Chang, Philippe Moreau, Jeffrey A. Zonder, Ralph V. Boccia, Kenneth H. Shain	15
17	Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma 2017 ·Blood ·Myra Robinson, Shebli Atrash, (unknown), Jared Block, Edward H. Lipford, (unknown), (unknown), (unknown), (unknown), Qing Zhang, David Foureau, (unknown), (unknown), James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Peter M. Voorhees, Saad Z. Usmani, Manisha Bhutani	0
18	A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease 2013 ·Clinical Cancer Research ·Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Z. Usmani, Helgi van de Velde, Xiang Qin, Thomas A. Puchalski, Brett M. Hall, Manjula Reddy, Ming Qi, Frits van Rhee	166
19	Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma 2008 ·Clinical Cancer Research ·Richard J. Jones, Qing Chen, Peter M. Voorhees, Ken H. Young, Nathalie Bruey-Sédano, Dajun Yang, Robert Z. Orlowski	27
20	Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma 2007 ·Clinical Cancer Research ·Peter M. Voorhees, Qing Chen, Deborah J. Kuhn, George W. Small, Sally A. Hunsucker, John S. Strader, Robert Corringham, Mohamed H. Zaki, Jeffrey A. Nemeth, Robert Z. Orlowski	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact